Shots: The DSMB recommended continued the dosing in the P- I/II clinical trial assessing AMT-130 in patients with a second higher-dose cohort, after review safety data from the first cohort of ten patients The first cohort of P- I/II trial for AMT-130 in 10 patients out of which six patients received treatment with AMT-130 and […]Read More
Shots: In the P-I SPICE study, the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21 NG-641 is […]Read More
Shots: The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented, de-identified clinical and genomic data to support Merck’s oncology efforts The data will be accessed through M2GEN’s ORIEN which is a network of 18 cancer centers across the US The collaboration provides utility […]Read More
Shots: The US FDA agreed to advance VERU-111 into a P-III study which will evaluate VERU-111 vs PBO in ~400 hospitalized patients in a ratio (2:1) with COVID-19 and are at high risk for ARDS. The study is anticipated to begin in Apr’2021 with clinical results expected in Q4’21 The P-II trial has demonstrated clinically […]Read More
Shots: Vir will receive ~$225M up front, $120M as an equity investment and $200M as regulatory milestones, ~300M as option payment and will be responsible to fund the development of VIR-2482 through the completion of the P-II trial GSK to get an exclusive option to co-develop VIR-2482 after Vir completes and reports P-II trial outcomes, […]Read More
Shots: The companies sign a purchase agreement with Covax to supply 40M doses of the COVID-19 vaccine. First deliveries are expected in Q1’ 2021, subject to the execution of supply agreements under the Covax Facility structure Covax includes an Advanced Market Commitment (AMC) financial mechanism under which Pfizer and BioNTech will provide access COVID-19 vaccines […]Read More
Shots: The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively Results: @12wks. clinical remission as per CDAI (45%/42% […]Read More
Shots: In terms of the agreement, lilly will commercialize the system, which is currently in development & will include an insulin pump developed & manufactured by ypsomed Ypsomed’s insulin pump has been marketed in europe since 2016, available in 21 countries as the mylife ypsopump. Lilly will commercialize a version of this insulin pump, along […]Read More
Shots: Microsoft enters collaboration with Illumina, Twist, and Western Digital to establish a roadmap for the industry towards the wider use of DNA data storage. These companies are the founding members of the alliance Ten additional technology leaders join founding members to together advance industry roadmap, set the stage for widespread adoption of new long-term […]Read More
Shots: The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
